<DOC>
	<DOC>NCT00902187</DOC>
	<brief_summary>To demonstrate bioequivalence of fesoterodine 4 mg tablets manufactured at Vega Baja, versus Zwickau.</brief_summary>
	<brief_title>A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviazâ„¢) In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Healthy male and/or female subjects Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Subjects with evidence or history of clinically significant urologic diseases A positive urine drug screen Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>